Monitoring agency report for the quarter ended June 30, 2025.
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CARE Ratings, the Monitoring Agency, has filed its quarterly report on the use of Rs. 114.30 crore raised by SMS Pharmaceuticals through a private placement of convertible share warrants in March 2024. The original objects were Capital Expenditure (Rs. 62.87 cr), Working Capital (Rs. 40 cr), and General Corporate Purposes (Rs. 11.43 cr). As of June 30, 2025, Rs. 28.57 crore had been utilized for stated objects, including Rs. 17.14 crore fully used for capital expenditure and Rs. 11.43 crore for working capital. An additional Rs. 38.10 crore was temporarily deployed for working capital needs and Rs. 0.01 crore remained in the monitoring account. GCP proceeds are yet to be utilized, and no deviations from the disclosed objects were observed. The capital expenditure timeline extends up to March 2026, with the agency noting that any delay in raising the balance funds could impact completion, though promoters are willing to infuse funds as required.
Neutral to mildly positive for shareholders — funds are being deployed in line with the disclosed plan with no deviations or misuse flagged. The temporary deployment of unutilized funds into working capital is permitted under the offer document, but the slow pace of warrant conversion and reliance on promoters for further funding remain points to watch.